← All drugs Report issue

tc-6499

Small moleculeexperimental

Clinical trial activity

2 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

2

Phase 3

0

Phase 4

0

Earliest trial started May 1, 2010 (NCT01149200)

Timeline

2010s

Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Jan 1, 2014
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Neuronal acetylcholine receptor; alpha3/beta4AGONIST
Neuronal acetylcholine receptor; alpha3/beta4 agonist
- Neuronal acetylcholine receptor subunit beta-4 (CHRNB4) ↗
- Neuronal acetylcholine receptor subunit alpha-3 (CHRNA3) ↗
- Neuronal acetylcholine receptor subunit alpha-3
Neuronal acetylcholine receptor; alpha4/beta2AGONIST
Neuronal acetylcholine receptor; alpha4/beta2 agonist
- Neuronal acetylcholine receptor subunit beta-2 (CHRNB2) ↗
- Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4) ↗
- Neuronal acetylcholine receptor protein beta-2 subunit
- Neuronal acetylcholine receptor protein alpha-4 subunit

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL3545353 ↗

Also known as

tc-6499
tc-6499
tc-6499-12

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02187094	Phase 1/Phase 2 (Phase 2)	Jun 1, 2014	Targacept
NCT01149200	Phase 2	May 1, 2010	Quotient, Targacept

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Targacept	For profit	2	2	1	2010
Quotient	For profit	1	0	1	2010

2 organizations

Page 1 / 1